Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Apr;117(8):1768–1772. doi: 10.1111/j.1476-5381.1996.tb15352.x

Synthesis and characterization of a selective peptide antagonist of neuropeptide Y vascular postsynaptic receptors.

M J Lew 1, R Murphy 1, J A Angus 1
PMCID: PMC1909543  PMID: 8732289

Abstract

1. A cyclic dimeric nonapeptide neuropeptide Y (NPY) receptor antagonist, 1229U91, was synthesized by Fmoc chemistry and dimerised in solution. Its effects were assayed in mesenteric arteries from rats and mice, and in rat vas deferens. 2. Mesenteric arteries were cannulated and pressurised to 55 mmHg and the external diameters continuously measured. NPY, PYY, Leu31Pro34NPY and NPY(13-36) each caused concentration-related contractions with the order of potency PYY > or = Leu31Pro34NPY = NPY > NPY (13-36), consistent with the Y1 receptor subtype. 3. 1229U91 had no agonist activity in the arteries but caused a concentration-related rightward shift of NPY (mouse arteries) or Leu31Pro34NPY (rat) concentration-response curves. The antagonism was competitive with pKBS of 7.69 +/- 0.15 and 7.47 +/- 0.13 in the mouse and rat arteries, respectively. 4. Sympathetic nerves in the vas deferens were stimulated with a single electrical field pulse every 20 s and the twitch responses recorded. NPY, PYY, Leu31Pro34NPY and NPY(13-36) inhibited the twitches with the order of potency PYY > NPY > NPY(13-36) >> Leu31Pro34NPY, consistent with the Y2 receptor subtype. 5. 1229U91 inhibited the vas deferens twitch with a shallow concentration-response curve and a time-course of inhibition distinct from that of NPY. 1229U91 (30 microM) did not cause a rightward shift of the NPY concentration-response curve. 1229U91 is at least 5 orders of magnitude less potent in the vas deferens than in rat brain Y2 binding assays reported by others, suggesting that the brain and vas deferens Y2 receptors are different. 6. It is concluded that 1229U91 is a competitive antagonist of NPY Y1 vascular receptors and has additional properties that inhibit the electrically evoked twitch of the rat vas deferens.

Full text

PDF
1768

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARIENS E. J., van ROSSUM J., KOOPMAN P. C. Receptor reserve and threshold phenomena. I. Theory and experiments with autonomic drugs tested on isolated organs. Arch Int Pharmacodyn Ther. 1960 Sep 1;127:459–478. [PubMed] [Google Scholar]
  2. Andriantsitohaina R., Stoclet J. C. Enhancement by neuropeptide Y (NPY) of the dihydropyridine-sensitive component of the response to alpha 1-adrenoceptor stimulation in rat isolated mesenteric arterioles. Br J Pharmacol. 1990 Feb;99(2):389–395. doi: 10.1111/j.1476-5381.1990.tb14714.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Daniels A. J., Matthews J. E., Slepetis R. J., Jansen M., Viveros O. H., Tadepalli A., Harrington W., Heyer D., Landavazo A., Leban J. J. High-affinity neuropeptide Y receptor antagonists. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9067–9071. doi: 10.1073/pnas.92.20.9067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Doughty M. B., Chu S. S., Miller D. W., Li K., Tessel R. E. Benextramine: a long-lasting neuropeptide Y receptor antagonist. Eur J Pharmacol. 1990 Aug 21;185(1):113–114. doi: 10.1016/0014-2999(90)90218-u. [DOI] [PubMed] [Google Scholar]
  5. Edvinsson L., Ekblad E., Håkanson R., Wahlestedt C. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol. 1984 Oct;83(2):519–525. doi: 10.1111/j.1476-5381.1984.tb16516.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fredholm B. B., Jansen I., Edvinsson L. Neuropeptide Y is a potent inhibitor of cyclic AMP accumulation in feline cerebral blood vessels. Acta Physiol Scand. 1985 Jul;124(3):467–469. doi: 10.1111/j.1748-1716.1985.tb07683.x. [DOI] [PubMed] [Google Scholar]
  7. Gustafsson H., Nilsson H. Endothelium-independent potentiation by neuropeptide Y of vasoconstrictor responses in isolated arteries from rat and rabbit. Acta Physiol Scand. 1990 Apr;138(4):503–507. doi: 10.1111/j.1748-1716.1990.tb08878.x. [DOI] [PubMed] [Google Scholar]
  8. Kenakin T. P., Bond R. A., Bonner T. I. Definition of pharmacological receptors. Pharmacol Rev. 1992 Sep;44(3):351–362. [PubMed] [Google Scholar]
  9. Laher I., Germann P., Bevan J. A. Neurogenically evoked cerebral artery constriction is mediated by neuropeptide Y. Can J Physiol Pharmacol. 1994 Sep;72(9):1086–1088. doi: 10.1139/y94-151. [DOI] [PubMed] [Google Scholar]
  10. Lew M. J., Angus J. A. Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol Sci. 1995 Oct;16(10):328–337. doi: 10.1016/s0165-6147(00)89066-5. [DOI] [PubMed] [Google Scholar]
  11. Lew M. J., Angus J. A. Reversible inhibition of neuronal uptake by benextramine, an irreversible presynaptic alpha-adrenoceptor antagonist. Eur J Pharmacol. 1984 Feb 10;98(1):27–34. doi: 10.1016/0014-2999(84)90105-5. [DOI] [PubMed] [Google Scholar]
  12. Lobaugh L. A., Blackshear P. J. Neuropeptide Y binding and inhibition of cAMP accumulation in human neuroepithelioma cells. Am J Physiol. 1990 May;258(5 Pt 1):C913–C922. doi: 10.1152/ajpcell.1990.258.5.C913. [DOI] [PubMed] [Google Scholar]
  13. Lundberg J. M., Pernow J., Tatemoto K., Dahlöf C. Pre- and postjunctional effects of NPY on sympathetic control of rat femoral artery. Acta Physiol Scand. 1985 Apr;123(4):511–513. doi: 10.1111/j.1748-1716.1985.tb07619.x. [DOI] [PubMed] [Google Scholar]
  14. Melchiorre C., Romualdi P., Bolognesi M. L., Donatini A., Ferri S. Binding profile of benextramine at neuropeptide Y receptor subtypes in rat brain areas. Eur J Pharmacol. 1994 Nov 14;265(1-2):93–98. doi: 10.1016/0014-2999(94)90228-3. [DOI] [PubMed] [Google Scholar]
  15. Neild T. O. Measurement of arteriole diameter changes by analysis of television images. Blood Vessels. 1989;26(1):48–52. [PubMed] [Google Scholar]
  16. Oshita M., Kigoshi S., Muramatsu I. Selective potentiation of extracellular Ca2+-dependent contraction by neuropeptide Y in rabbit mesenteric arteries. Gen Pharmacol. 1989;20(3):363–367. doi: 10.1016/0306-3623(89)90274-7. [DOI] [PubMed] [Google Scholar]
  17. Plotek Y., Atlas D. Characterization of benextramine as an irreversible alpha-adrenergic blocker and as a blocker of potassium-activated calcium channels. Eur J Biochem. 1983 Jul 1;133(3):539–544. doi: 10.1111/j.1432-1033.1983.tb07497.x. [DOI] [PubMed] [Google Scholar]
  18. Saville V. L., Maynard K. I., Burnstock G. Neuropeptide Y potentiates purinergic as well as adrenergic responses of the rabbit ear artery. Eur J Pharmacol. 1990 Feb 6;176(2):117–125. doi: 10.1016/0014-2999(90)90519-c. [DOI] [PubMed] [Google Scholar]
  19. Stupecky G. L., Murray D. L., Purdy R. E. Vasoconstrictor threshold synergism and potentiation in the rabbit isolated thoracic aorta. J Pharmacol Exp Ther. 1986 Sep;238(3):802–808. [PubMed] [Google Scholar]
  20. Tatemoto K. Neuropeptide Y and its receptor antagonists. Use of an analog mixture-screening strategy. Ann N Y Acad Sci. 1990;611:1–6. doi: 10.1111/j.1749-6632.1990.tb48917.x. [DOI] [PubMed] [Google Scholar]
  21. Tessel R. E., Miller D. W., Misse G. A., Dong X., Doughty M. B. Characterization of vascular postsynaptic neuropeptide Y receptor function and regulation. 1. NPY-induced constriction in isolated rat femoral artery rings is mediated by both Y1 and Y2 receptors: evidence from benextramine protection studies. J Pharmacol Exp Ther. 1993 Apr;265(1):172–177. [PubMed] [Google Scholar]
  22. Wahlestedt C., Reis D. J. Neuropeptide Y-related peptides and their receptors--are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol. 1993;33:309–352. doi: 10.1146/annurev.pa.33.040193.001521. [DOI] [PubMed] [Google Scholar]
  23. Wahlestedt C., Reis D. J., Yoo H., Adamsson M., Andersson D., Edvinsson L. A novel inositol phosphate selectively inhibits vasoconstriction evoked by the sympathetic co-transmitters neuropeptide Y (NPY) and adenosine triphosphate (ATP). Neurosci Lett. 1992 Aug 31;143(1-2):123–126. doi: 10.1016/0304-3940(92)90247-5. [DOI] [PubMed] [Google Scholar]
  24. Xiong Z., Bolzon B. J., Cheung D. W. Neuropeptide Y potentiates calcium-channel currents in single vascular smooth muscle cells. Pflugers Arch. 1993 Jun;423(5-6):504–510. doi: 10.1007/BF00374948. [DOI] [PubMed] [Google Scholar]
  25. Xiong Z., Cheung D. W. Neuropeptide Y inhibits Ca(2+)-activated K+ channels in vascular smooth muscle cells from the rat tail artery. Pflugers Arch. 1994 Dec;429(2):280–284. doi: 10.1007/BF00374324. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES